0001179110-18-004702.txt : 20180320
0001179110-18-004702.hdr.sgml : 20180320
20180320173633
ACCESSION NUMBER: 0001179110-18-004702
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180316
FILED AS OF DATE: 20180320
DATE AS OF CHANGE: 20180320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hack Andrew A. F.
CENTRAL INDEX KEY: 0001657434
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37687
FILM NUMBER: 18702753
MAIL ADDRESS:
STREET 1: 300 THIRD STREET, FIRST FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Editas Medicine, Inc.
CENTRAL INDEX KEY: 0001650664
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464097528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11 HURLEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-401-9000
MAIL ADDRESS:
STREET 1: 11 HURLEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
edgar.xml
FORM 4 -
X0306
4
2018-03-16
0
0001650664
Editas Medicine, Inc.
EDIT
0001657434
Hack Andrew A. F.
C/O EDITAS MEDICINE, INC.
11 HURLEY ST.
CAMBRIDGE
MA
02141
0
1
0
0
Chief Financial Officer
Common Stock
2018-03-16
4
M
0
6000
6.48
A
6000
D
Common Stock
2018-03-16
4
S
0
6000
39.43
D
0
D
Common Stock
2018-03-19
4
M
0
6000
6.48
A
6000
D
Common Stock
2018-03-19
4
S
0
6000
37.65
D
0
D
Common Stock
2018-03-20
4
M
0
5000
6.48
A
5000
D
Common Stock
2018-03-20
4
S
0
5000
37.51
D
0
D
Common Stock
2018-03-20
4
M
0
1000
6.48
A
1000
D
Common Stock
2018-03-20
4
S
0
1000
38.39
D
0
D
Common Stock
2018-03-20
4
M
0
22000
24.6
A
22000
D
Common Stock
2018-03-20
4
S
0
22000
37.91
D
0
D
Stock Option (right to buy)
6.48
2018-03-16
4
M
0
6000
0
D
2025-09-13
Common Stock
6000
60513
D
Stock Option (right to buy)
6.48
2018-03-19
4
M
0
6000
0
D
2025-09-13
Common Stock
6000
54513
D
Stock Option (right to buy)
6.48
2018-03-20
4
M
0
6000
0
D
2025-09-13
Common Stock
6000
48513
D
Stock Option (right to buy)
24.60
2018-03-20
4
M
0
22000
0
D
2027-02-28
Common Stock
22000
70500
D
The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017.
This transaction was executed in multiple trades at prices ranging from $39.02 to $40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $37.29 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $37.13 to $38.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $38.23 to $38.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $37.86 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.
This amount includes an additional 2,851 option shares relating to the portion of this award constituting an Incentive Stock Option that the Reporting Person inadvertently omitted in that Form 4 filed by the Reporting Person with the SEC on February 16, 2018.
This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021.
/s/ Andrew Hack
2018-03-20